missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ NNT1 Polyclonal Antibody

Rabbit Polyclonal Antibody
Brand: Invitrogen™ PA529935
This item is not returnable.
View return policy
Description
Recommended positive controls: human CLCF1-transfected 293T cells. Predicted reactivity: Mouse (96%), Rat (96%). Store product as a concentrated solution. Centrifuge briefly prior to opening the vial.
NNT-1/BCSF-3 is a neurotrophic factor with B-cell-stimulating capabilities. Expressed in the lymph nodes and spleen, NNT-1/BCSF-3 activates glycoprotein 130 (gp130) and leukemia inhibitory factor receptor member b (LIFR-b) by binding and inducing the tyrosine phosphorylation of these receptors. In vitro, it supports the survival of chick embryo motor and sympathetic neurons. In mice, NNT-1/BCSF-3 induces serum amyloid A, causes body weight loss, and B cell hyperplasia associated with increases in serum IgG and IgM.
Specifications
| NNT1 | |
| Polyclonal | |
| Unconjugated | |
| CLCF1 | |
| b cell-stimulating factor 3; B-cell stimulating factor 3; B-cell stimulatory factor 3; B-cell-stimulating factor 3; Bsf3; BSF-3; Cardiotrophin-like cytokine factor 1; CISS2; Clc; CLCF1; CRLF1 associated cytokine-like factor 1; neurotrophin-1/B-cell stimulating factor-3; NNT1; NNT-1; NNT-1/BSF-3; Novel neurotrophin-1; NR6 | |
| Rabbit | |
| Antigen affinity chromatography | |
| RUO | |
| 23529 | |
| Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles. | |
| Liquid |
| Immunohistochemistry (Paraffin), Western Blot, Immunocytochemistry | |
| 1 mg/mL | |
| 0.1M tris glycine with 20% glycerol and 0.01% thimerosal; pH 7 | |
| Q9UBD9 | |
| CLCF1 | |
| Recombinant protein encompassing a sequence within the center region of human NNT1. The exact sequence is proprietary. | |
| 100 μL | |
| Primary | |
| Human | |
| Antibody | |
| IgG |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction